NCT05014464View on ClinicalTrials.gov

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 13, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

August 8, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Crizotinib

Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER